Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Dec 17;9(3):1167–1172. doi: 10.3892/ol.2014.2808

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2015, Spandidos Publications

This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.

PMC Copyright notice

The CD14⁺HLA-DR^low/− MDSCs are upregulated in CLL patients. (A) Representative HLA-DR expression in CD14⁺ monocyte population of the control group, MBL patients and CLL patients. (B) Frequency of CD14⁺HLA-DR^low/− MDSCs in CD14⁺ monocytes of CLL patients (42.1±14.5%; n=49) were significantly elevated compared with MBL (24.95±8.1%; n=23) and control (6.1±2.2%; n=21) patients (both were P<0.0001). (C) Frequency of CD14⁺HLA-DR^low/− MDSCs in CD14⁺ monocytes were significantly increased in advanced stages compared with the stage I CLL patients (stage II: n=18; P<0.0001; stage III: n=12; P<0.0001; stage IV: n=7; P=0.0005). ^***P<0.001. CD14, cluster of differentiation 14; HLA, human leukocyte antigen; MDSCs, myeloid-derived suppressor cells; CLL, chronic lymphocytic leukemia; MBL, monoclonal B cell lymphocytosis.